References
- Morris K. R., Griesser U. J., Eckhardt C. J., Stowell J. G. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv. Drug Deliv. Rev. 2001; 48(1)91–114
- Brittain H. G. Effects of mechanical processing on phase composition. J. Pharm. Sci. 2002; 91(7)1573–1580
- Byrn S., Pfeiffer R., Ganey M., Hoiberg C., Poohikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm. Res. 1995; 12(7)945–954
- Chawla G., Bansal A. K. Polymorphism of pharmaceuticals: challenges and opportunities. Express Pharm. Pulse 2003; 9(48)10
- Chawla G., Bansal A. K. Regulatory issues related to polymorphism. Express Pharm. Pulse 2003; 9(49)8, 20
- Craig D. Q.H., Royall P. G., Kett V. L., Hopton M. L. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze‐dried systems. Int. J. Pharm. 1999; 179(1)179–207
- Chawla G., Gupta P., Thilagavathi R., Chakraborti A. K., Bansal A. K. Characterization of solid‐state forms of Celecoxib. Eur. J. Pharm. Sci. 2003; 20(3)305–317
- Otsuka M., Matsumoto T., Kaneniwa N. Effects of mechanical energy of multi‐tableting compression on the polymorphic transformations of chlorpropamide. J. Pharm. Pharmacol. 1989; 41(1)665–669
- Bernstein J., Davey R. J., Henck J.‐O. Concomitant polymorphs. Angew. Chem., Int. Ed. 1999; 38: 3441–3461
- Ketolainen J., Poso A., Viitasaari V., Gynther J., Pirttimaki J., Laine E., Paronen P. Changes in solid‐state structure of cyclophosphamide monohydrate induced by mechanical treatment and storage. Pharm. Res. 1995; 12(2)299–304
- Banker G. S., Anderson N. R. L. Lachman, H. A. Lieberman, J. L. KanigTablets. The Theory and Practice of Industrial Pharmacy, . Varghese Publishing House, India 1991; 293–345
- Brittain H. G., Fiese E. F. J. SwarbrickEffects of pharmaceutical processing on drug polymorphs and solvates. Polymorphism in Pharmaceutical Solids, . Marcel Dekker Inc., New York 1999; Vol. 95: 331–362
- Sonnergaard J. M. A critical evaluation of the Heckel equation. Int. J. Pharm. 1999; 193(1)63–71
- Sun C., Grant D. J.W. Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm. Res. 2001; 18(3)274–280
- Ragnarsson G. J. SwarbrickForce‐displacement and network measurements. Pharmaceutical Powder Compaction Technology, . Marcel Dekker Inc., New York 1996; 77–98
- Jetzer W., Leuenberger H., Sucker H. The compressibility and compactability of pharmaceutical powders. Pharm. Tech. 1983; 4: 33–39
- Marshall K. L. Lachman, H. A. Lieberman, J. L. KanigCompression and consolidation of powdered solids. The Theory and Practice of Industrial Pharmacy, . Varghese Publishing House, India 1991; 66–99
- York P. Crystal engineering and particle design for the powder compaction process. Drug Dev. Ind. Pharm. 1992; 18(6&7)331–365
- Chan H. K., Doelker E. Polymorphic transformation of some drugs under compression. Drug Dev. Ind. Pharm. 1985; 11(2&3)315–332
- Black D. B., Lovering E. G. Estimation of degree of crystallinity in digoxin by x‐ray and infrared methods. J. Pharm. Pharmacol. 1977; 29: 684–687